These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 14612517

  • 1. Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission.
    Schiffer IB, Gebhard S, Heimerdinger CK, Heling A, Hast J, Wollscheid U, Seliger B, Tanner B, Gilbert S, Beckers T, Baasner S, Brenner W, Spangenberg C, Prawitt D, Trost T, Schreiber WG, Zabel B, Thelen M, Lehr HA, Oesch F, Hengstler JG.
    Cancer Res; 2003 Nov 01; 63(21):7221-31. PubMed ID: 14612517
    [Abstract] [Full Text] [Related]

  • 2. Dephosphorylation of p-ERK1/2 in relation to tumor remission after HER-2 and Raf1 blocking therapy in a conditional mouse tumor model.
    Hausherr CK, Schiffer IB, Gebhard S, Banić A, Tanner B, Kolbl H, Thoenes E, Beckers T, Spangenberg C, Prawitt D, Trost T, Zabel B, Oesch F, Hermes M, Hengstler JG.
    Mol Carcinog; 2006 May 01; 45(5):302-8. PubMed ID: 16496387
    [Abstract] [Full Text] [Related]

  • 3. Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase.
    Baasner S, von Melchner H, Klenner T, Hilgard P, Beckers T.
    Oncogene; 1996 Sep 05; 13(5):901-11. PubMed ID: 8806679
    [Abstract] [Full Text] [Related]

  • 4. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.
    Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung MC.
    Clin Cancer Res; 2000 Jan 05; 6(1):250-9. PubMed ID: 10656456
    [Abstract] [Full Text] [Related]

  • 5. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
    Shi Y, Chatterjee SJ, Brands FH, Shi SR, Pootrakul L, Taylor CR, Datar R, Cote RJ.
    BJU Int; 2006 Jan 05; 97(1):170-8. PubMed ID: 16336351
    [Abstract] [Full Text] [Related]

  • 6. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S, Tinnirello A, Di Stefano P, Bisarò B, Ambrosino E, Castellano I, Sapino A, Arisio R, Cavallo F, Forni G, Glukhova M, Silengo L, Altruda F, Turco E, Tarone G, Defilippi P.
    Cancer Res; 2006 May 01; 66(9):4672-80. PubMed ID: 16651418
    [Abstract] [Full Text] [Related]

  • 7. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
    Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung MC.
    Oncogene; 1997 Feb 06; 14(5):561-8. PubMed ID: 9053854
    [Abstract] [Full Text] [Related]

  • 8. Soy isoflavone genistein modulates cell cycle progression and induces apoptosis in HER-2/neu oncogene expressing human breast epithelial cells.
    Katdare M, Osborne M, Telang NT.
    Int J Oncol; 2002 Oct 06; 21(4):809-15. PubMed ID: 12239620
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.
    Menendez JA, Mehmi I, Verma VA, Teng PK, Lupu R.
    Mol Carcinog; 2004 Nov 06; 41(3):164-78. PubMed ID: 15390078
    [Abstract] [Full Text] [Related]

  • 10. [Effects of Her-2/neu siRNA-mediated gene silencing on cell cycle and apoptosis of lung adenocarcinoma cells].
    Ren SH, Wang JW, Zhang L.
    Zhonghua Yi Xue Za Zhi; 2005 Jun 15; 85(22):1530-4. PubMed ID: 16179111
    [Abstract] [Full Text] [Related]

  • 11. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
    Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ.
    Oncogene; 1997 Jul 31; 15(5):537-47. PubMed ID: 9247307
    [Abstract] [Full Text] [Related]

  • 12. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
    Zhang L, Lau YK, Xia W, Hortobagyi GN, Hung MC.
    Clin Cancer Res; 1999 Feb 31; 5(2):343-53. PubMed ID: 10037184
    [Abstract] [Full Text] [Related]

  • 13. Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu.
    Roh H, Pippin J, Drebin JA.
    Cancer Res; 2000 Feb 01; 60(3):560-5. PubMed ID: 10676637
    [Abstract] [Full Text] [Related]

  • 14. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
    Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R.
    Cancer Res; 2006 Aug 15; 66(16):8266-73. PubMed ID: 16912207
    [Abstract] [Full Text] [Related]

  • 15. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis.
    Afonja O, Juste D, Das S, Matsuhashi S, Samuels HH.
    Oncogene; 2004 Oct 21; 23(49):8135-45. PubMed ID: 15361828
    [Abstract] [Full Text] [Related]

  • 16. Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer.
    Xing X, Matin A, Yu D, Xia W, Sorgi F, Huang L, Hung MC.
    Cancer Gene Ther; 1996 Oct 21; 3(3):168-74. PubMed ID: 8725881
    [Abstract] [Full Text] [Related]

  • 17. Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors.
    Giavazzi R, Giuliani R, Coltrini D, Bani MR, Ferri C, Sennino B, Tosatti MP, Stoppacciaro A, Presta M.
    Cancer Res; 2001 Jan 01; 61(1):309-17. PubMed ID: 11196179
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Construction of autocatalytic caspase-3 driven by amplified human telomerase reverse transcriptase promoter and its enhanced efficacy of inducing apoptosis in human ovarian carcinoma].
    Song Y, Shen K, He CX.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Sep 01; 42(9):617-22. PubMed ID: 17983518
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.